Ariad Pharmaceuticals Inc fka ARIA

[Sikmarson]

“We are now well positioned to complete pricing and reimbursement negotiations in Europe and to ensure that Iclusig is available to appropriate Philadelphia-chromosome positive leukaemia patients,”
said Jonathan E. Dickinson, general manager, ARIAD Pharmaceuticals (Europe). “The authorized indications and the favorable benefit-risk balance of Iclusig give healthcare providers the ability to optimize the use of Iclusig in patients with resistant or intolerant CML.”